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Background: The optimal treatment for pulmonary mucoepidermoid carcinoma (MEC), a rare type of tumor, has
not been established yet. This study analyzed the survival of pulmonary MEC patients and attempted to find clues
for optimal treatment.
Methods: A total of 21 patients with pulmonary MEC from November 2004 to January 2011 were included in the
investigation. Immunohistochemistry, epidermal growth factor receptor (EGFR) mutation, and survival were
retrospectively studied.
Results: Among the 21 pulmonary MEC patients, 17 were diagnosed with low-grade malignancy and 4 with
high-grade malignancy through pathological examination. The prognosis was found to be poor in the presence of
lymph nodes. The expression rates of EGFR and HER2 were 28.6% and 0%, respectively, which correlated with
neither grade nor prognosis. The mutation rate of EGFR was 0. Log-rank test results indicated that age, grade,
lymph node metastasis, and tumor-node-metastasis stage were prognostic factors.
Conclusion: Age, grade, lymph node metastasis and tumor-node-metastasis stage correlate with the survival of
pulmonary MEC patients.
Trial registration: This study was approved and registered by the Ethics Committee of Zhongshan Hospital.
Written informed consent was obtained from all participants prior to treatment.
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Pulmonary mucoepidermoid carcinoma (MEC) is rare,
accounting for approximately 0.2% of all malignant lung
tumors [1]. This tumor is believed to be indolent; how-
ever, little is known about its clinical features because of
the low incidence rate. No consensus on optimal treat-
ment strategy is available, and surgery is the common
choice [2]. Treatment involving epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs)
showed promising outcome for MEC patients [3]. How-
ever, these results need confirmation. In the present
study, we detected the expression rates of EGFR and
HER2 of MEC, analyzed EGFR mutation status, and
explored the prognostic factors of survival. The results* Correspondence: doctorwangqun@yahoo.com.cn
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reproduction in any medium, provided the orof the present study may serve as a basis for the devel-
opment of a treatment strategy for MEC.Methods
Clinical features, immunohistochemistry, and EGFR
mutation analysis
Patients who presented with pathologically confirmed
primary pulmonary MEC at the Division of Thoracic
Surgery, Zhongshan Hospital between November 2004
and January 2011 were enrolled in this study. This study
was approved by the Ethics Committee of Zhongshan
Hospital. Written informed consent was obtained from
all participants prior to treatment. Follow-ups were con-
ducted via telephone interview by contributing physi-
cians. For additional analyses, the data were analyzed
anonymously, wherein informed consent was not
required. Table 1 describes the clinical features of the 21
patients.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical features of patients
Number
Male:female 10:11
Age (mean) 43.4
Smoking 2/21
Initial symptoms
Cough 7
Bloody sputum 3
Hemoptysis 2
Cough and bloody sputum 2
Cough and hemoptysis 1
Dyspnea 1
Chest pain 1
Asymptomatic 4
Tumor location
Right main bronchus 1
Left main bronchus 2
Intermediate bronchus 2
Right upper lobe 3
Right middle lobe 2
Right inferior lobe 5
Left upper lobe 4
Left inferior lobe 2
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Paraffin-embedded tissues of tumors were stained for the
detection of EGFR and HER2 expressions by immunohis-
tochemistry. Novocastra liquid mouse monoclonal anti-
body epidermal growth factor receptor (Leica Biosystems,
Newcastle, UK) and polyclonal rabbit anti-human c-erbB-2
oncoprotein (Dako, Glostrup, Denmark) for EGFR and
HER-2, respectively, were provided by the Division of Path-
ology of our hospital. EGFR and HER2 expressions were
evaluated according to previously described criteria [4,5].
Exons 18-21 of EGFR were examined by direct se-
quencing. The analyzed sites were G719S, exon 19,
T790M, L858R, and L861Q.
Statistical analysis
Cumulative survival rates were calculated by the Kaplan-
Meier method, and the survival curves were compared
using the log-rank test. The chi-square test was performed
to determine the relationship among EGFR/HER2 expres-
sion, differentiation grade, and lymph node metastasis.
Univariate and multivariate analyses using Cox's propor-
tional hazard model were conducted to obtain the risk fac-
tors of MEC-related death and recurrence. The
multivariate analysis was conducted by forward stepwise
regression. All analyses were performed using SPSS soft-
ware version 13.0 (SPSS Inc., Chicago, IL, USA).Results
Treatments and pathology
None of the patients was given neoadjuvant therapy, and
all patients underwent surgery. Lobectomies were per-
formed on 13 patients. The other patients underwent
bilobectomy (n = 2), sleeve lobectomy (n = 2), segmental
lung resection (n = 1), local resection (n = 1), bronchial
sleeve resection and reconstruction (n = 1), and pneu-
monectomy with resection and reconstruction of super-
ior vena cava and atrium (n = 1).
Postoperative pathology showed low-grade MEC in 17
patients and high-grade MEC in 4 patients (Figure 1)
according to the criteria described by Yousem and
Hochholzer [6]. Based on the tumor-node-metastasis
(TNM) staging system of the American Joint Committee
on Cancer and the International Union against Cancer
(7th edition, 2009), more than half of the patients were
in stage I (Table 2). Lymph node dissection was not per-
formed in two cases.
One patient (Number 14) received adjuvant radiother-
apy because the surgical margin was positive. One patient
(Number 12) with tumor (T2aN1M0) received adjuvant
chemotherapy because of the physician’s advice.
Expressions of EGFR and HER2
Table 2 describes the expression of EGFR, and the spe-
cimen was considered positive if the percentage/inten-
sity was >10%+. The positive rates of EGFR and HER2
were 28.6% (6/21) and 0%, respectively (Figure 2). The
expression of EGFR was not associated with differenti-
ation (P = 1) or lymph node metastasis (P = 0.28).
EGFR mutation
Among the 21 pulmonary MEC cases, 19 were available
for EGFR mutational analysis. All the tumors examined
were negative for EGFR mutation.
Survival
One patient (Number 15) died in the hospital because of
tumor invasion at the carina, right pulmonary artery, su-
perior vena cava, and right atrium. The tumor was low
grade and was at stage IIIB. As mentioned previously,
the patient received pneumonectomy with resection and
reconstruction of the superior vena cava and atrium. At
24 days after surgery, the patient died of respiratory fail-
ure. Follow-up information for the other 20 patients is
listed in Table 2.
The follow-up period for the 16 low-grade tumor cases
ranged from 5 to 77 months (mean: 46.6 months). The
average age of the patients was 38.8 years. Among these
patients, 15 survived and 1 died. The patient (Number
8) was at stage Ib (T2N0M0). His disease recurred at 40
months after surgery, no subsequent treatment was
given, and he died a month later.
Figure 1 Representative images of hematoxylin and eosin-stained pathologic specimens. Low-grade tumor was composed of epideroid,
intermediate, columnar, and goblet cells. The goblet cells were rich in mucin. (A) Low-grade mucoepidermoid carcinoma (MEC), 100×; (B) low-
grade MEC, 400×. The cellular component of high-grade tumor was the same as that of low-grade tumor, but squamoid cells were predominant.
Cytologic atypia and mitotic activity were more common in high-grade tumor. (C) High-grade MEC, 100×; (D) high-grade MEC, 400×.
Table 2 Pathology and survival information
Number Grade Stage T N M EGFR IHC EGFR
mutation
Recurrence
metastasis
Survival status OS/month/
month
PFS/month/
month
1 Low Ia 1a 0 0 50%++ N/A - Alive 29 29
2 Low Ia 1a 0 0 0 - - Alive 76 76
3 Low Ia 1a 0 0 0 - - Alive 77 77
4 Low Ia 1b 0 0 0 - - Alive 62 62
5 Low Ia 1b 0 0 0 - - Alive 5 5
6 Low Ib 2a 0 0 30%+ - - Alive 22 22
7 Low Ib 2a 0 0 0 - - Alive 46 46
8 Low Ib 2a 0 0 0 - Recurrence Dead 41 40
9 Low Ib 2a 0 0 90%+ - - Alive 66 66
10 Low Ib 2a 0 0 0 - - Alive 67 67
11 Low Ib 2a 0 0 0 - - Alive 67 67
12 Low IIa 2a 1 0 20%+ - - Alive 29 29
13 Low IIb 3 0 0 0 - - Alive 5 5
14 Low IIb 3 0 0 0 - - Alive 54 54
15 Low IIIb 4 2 0 90%++ - - Perioperative dead - -
16 Low - 3 x 0 0 N/A - Alive 74 74
17 Low - 1b x 0 0 - - Alive 25 25
18 High Ia 1a 0 0 0 - - Alive 47 47
19 High IIb 2b 1 0 100%+ - Contralateral lung
metastasis
Dead 65 63
20 High IIIa 2a 2 0 0 - Recurrence Dead 31 30
21 High IIIa 2a 2 0 0 - Liver metastasis Dead 23 15
EGFR epidermal growth factor receptor, IHC immunohistochemistry, N/A not available, OS overall survival, PFS Progression-free survival, TNM tumor-node-metastasis.
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Figure 2 Representative images of immunohistochemistry staining. (A) Positive EGFR expression, 100×; (B) positive EGFR expression, 400×;
(C) false-positive HER2 expression because only cytoplasmic staining was observed, 100×; (D) false-positive HER2 expression because only
cytoplasmic staining was observed, 400×.
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cases ranged from 23 to 65 months (mean: 41.5
months). The average age of the patients was 62.0 years.
Among these patients, three died and one survived. Pa-
tient Number 19 (stage IIb, T2bN1M0) had contralateral
lung metastasis at 63 months after surgery and then died
2 months later. Patient Number 20 (stage IIIa,
T2aN2M0) experienced a recurrence at 30 months after
surgery and died a month later. Both patients mentioned
earlier did not receive any subsequent treatment. Patient
Number 21 was at stage IIIa (T2aN2M0). After disease
metastasized to the liver at 15 months after surgery, the
patient started with gefitinib treatment (250 mg/d). The
patient died eight months later.
Kaplan-Meier curve of overall survival (OS) (Figure 3)
and progression-free survival (PFS) (Figure 4) showed
that age, differentiation grade, lymph node metastasis,
and TNM stage were associated with OS and PFS. Uni-
variate Cox proportional hazard regression analyses
showed that age, grade, lymph node metastasis, and
TNM stage were prognostic factors (Table 3). Age,
grade, lymph node metastasis, and TNM stage were
included in the multivariate analysis. Lymph node me-
tastasis was the only variate in the regression equation
of OS (hazard ratio (HR) = 0.06, 95% confidence interval
(95% CI): 0.01 to 0.62, P = 0.018) and PFS (HR = 0.06,
95% CI: 0.01 to 0.61, P = 0.017).
Discussion
Pulmonary MEC, which was firstly reported by Smetana
et al. [7], was derived from the exocrine duct of thetracheobronchial submucosal glands. The clinical features
of the 21 patients were similar to the results reported pre-
viously [6,8]. Making an exact diagnosis of pulmonary
MEC before surgery is difficult because the clinical mani-
festations and auxiliary examination findings are unspe-
cific. High-grade MEC is often difficult to distinguish
from adenosquamous carcinoma. Keratinization, a feature
of adenosquamous carcinoma, is absent in high-grade
MEC. Another difference is that the surface epithelium of
MEC rarely shows in situ carcinoma. We performed
immunohistochemistry staining to ensure the diagnosis.
TTF-1 and surfactant are commonly positive in adenos-
quamous carcinoma, while they are always negative in
high-grade mucoepidermoid carcinoma of lung.
The tumor is classified as either low grade or high
grade according to histology appearance, cellular atypia,
mitotic activity, local invasion, and necrosis. The bio-
logical behavior of pulmonary MEC was believed to be
associated with differentiation [6]. Well-differentiated
tumors present benign behavior, and vice versa. The
prognosis of low-grade tumor patients who underwent
surgery is better than that of high-grade tumor patients
who underwent surgery. However, none of the previous
studies mentioned HR. Comparing the prognosis of
poorly differentiated and well/moderately differentiated
non-small cell lung cancer (NSCLC), HR was 1.15
(95% CI, 0.81 to 1.64, P = 0.42), which is not statisti-
cally significant [9]. In this research, according to the
Kaplan-Meier curve and HR, low-grade tumor cases
had advantage over high-grade tumor cases in OS and
PFS.
Figure 3 Kaplan-Meier curves of overall survival (OS) for variates: (A) age, (B) grade, (C) lymph node metastasis, and (D) TNM stage.
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nosis of older patients is worse and that hilar lymph
node metastasis indicates worse prognosis. In the
series reported by Vadasz and Egervary [2], only high-
grade tumors develop lymph node metastasis. In the
present study, univariate analysis showed that age and
TNM stage were correlated with OS and PFS. How-
ever, multivariate regression analysis revealed that
lymph node metastasis was the only independent prog-
nostic factor. It should be noticed that multivariate
analysis should be based on a large sample, and our
study is limited by the small sample. We are just try-
ing to get clues for treatment and prognosis, and we
can only assume that maybe lymph node metastasis is
the most important prognostic factor of pulmonary
MEC.To date, surgery is the preferred treatment of pulmon-
ary MEC, in which tumor location determines the surgi-
cal procedure. Among the 21 cases, 16 tumors were
found in the lobar bronchi, for which lobectomy was the
most common surgical procedure, accounting for 61.9%
(13/21) of the cases. Sleeve lobectomy should be consid-
ered when the primary bronchus is invaded, and pneu-
monectomy is the last choice. In this investigation, only
one patient underwent pneumonectomy because of
tumor invasion at the carina, right pulmonary artery, su-
perior vena cava, and right atrium.
No evidence proved the effect of chemotherapy or
radiotherapy. Some studies reported that chemotherapy
or radiotherapy is inefficient [1,10]. Although paclitaxel
is active in MEC of salivary glands [11], its effectiveness
in pulmonary MEC has yet to be determined. Therefore,
Figure 4 Kaplan-Meier curves of progression-free survival (PFS) for variates: (A) age, (B) grade, (C) lymph node metastasis, and (D) TNM
stage.
Table 3 Hazard ratio of variates for overall survival and
progression-free survival
Overall survival Progression-free survival
HR 95% CI P value HR 95% CI P value
Age 1.22 1.01-1.48 0.044 1.22 1.01-1.48 0.044
EGFR 0.80 0.08-7.82 0.845 0.85 0.09-8.38 0.888
Grade 0.08 0.01-0.75 0.028 0.08 0.01-0.74 0.026
T 0.93 0.10-8.98 0.946 0.91 0.10-8.88 0.937
N 0.06 0.01-0.62 0.018 0.06 0.01-0.61 0.017
TNM stage 0.09 0.01-0.87 0.037 0.09 0.01-0.85 0.036
CI confidence interval, EGFR epidermal growth factor receptor, HR hazard ratio,
TNM tumor-node-metastasis.
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apy or radiotherapy. Our present data showed that 3/4
of high-grade pulmonary MEC patients developed lymph
node metastasis, and the prognosis was dismal. As a type
of NSCLC, adjuvant therapy was indicated for pulmon-
ary MEC when lymph node metastasis occurred. Thus,
the treatment of pulmonary MEC with lymph node me-
tastasis using surgery alone poses some problems. Al-
though the prognosis of patients with lymph node
involving pulmonary MEC was poor, no subsequent
therapy was proven to be optimal. We supposed that
treatment involving EGFR TKIs may be a choice for pul-
monary MEC. In a previous study, a pulmonary MEC
patient received gefitinib after the tumor metastasized to
chest wall and contralateral lung [3]. CT scans revealed
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that no EGFR tyrosine kinase mutation was detected in
the chest wall mass. In the present study, patient Num-
ber 21 had a prolonged survival period of eight months
after gefitinib administration. Patient Numbers 19 and
20 survived for two months and one month after pro-
gression without any subsequent treatment, respectively.
Assuming that EGFR/HER2 was associated with sur-
vival, we analyzed the expressions of EGFR and HER2 in
the 21 cases. The lack of HER2 expression was coinci-
dent with the previous results. EGFR expression was not
common either in the lung or salivary glands, which dif-
fered from the results of previous studies [12,13]. EGFR
expression was correlated with neither differentiation
grade nor prognosis. In MEC of salivary glands, EGFR
expression was common, whereas HER-2 expression was
not [12]. Han et al. [3] detected EGFR and HER-2
expressions in six pulmonary MEC patients, with posi-
tive rates of 4/6 and 0, respectively. Macarenco et al.
[13] reported that 92% (11/12) of pulmonary MEC speci-
mens were positive for EGFR expression. In MEC of sal-
ivary glands, EGFR expression is correlated with
histological grade but not with patient outcome [14].
The relationship between EGFR expression and prog-
nosis in NSCLC is disputable, and EGFR mutation status
is considered as a strong predictor for EGFR TKI admin-
istration [15]. A previous study reported that MEC has
EGFR mutation in 40% (2/5) of cases [3]. By contrast,
EGFR mutation was negative in the present research. Al-
though the results were negative, we cannot conclude
that treatment involving EGFR TKIs is ineffective for
MEC. NCI-H292 cell line, a pulmonary MEC cell line
with wild-type EGFR, demonstrates enhanced sensitivity
to gefitinib compared with other NSCLC lines with
wild-type EGFR [16]. EGFR is not the only target of gefi-
tinib. Some clinicians [17] assumed that t(11;19) and
associated fusion CRTC1-MAML2 may be the targets of
EGFR TKI therapy. However, further studies need to be
conducted to clarify the mechanism of EGFR TKIs.
Conclusion
Age, grade, lymph node metastasis and tumor-node-
metastasis stage correlate with the survival of pulmonary
MEC patients.
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